Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 4 25 IN DEXTROSE 20 IN PLASTIC CONTAINER versus AMINOSYN II 7 W ELECTROLYTES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 4 25 IN DEXTROSE 20 IN PLASTIC CONTAINER versus AMINOSYN II 7 W ELECTROLYTES.
AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER vs AMINOSYN II 7% W/ ELECTROLYTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn II 4.25% in Dextrose 20% provides amino acids for protein synthesis and dextrose as a caloric source. Amino acids are utilized for tissue repair and maintenance, while dextrose provides energy via glycolysis and oxidative phosphorylation.
Provides essential and non-essential amino acids for protein synthesis, promotes nitrogen balance, and serves as a caloric source in parenteral nutrition.
Intravenous infusion of 500 mL to 1 L per day. Typical rate: 1-2 mL/min (60-120 mL/hr). Adjust based on caloric and fluid requirements.
Adults: 500 mL to 2000 mL/day intravenously via central line at a rate not exceeding 100 mL/hour. Dosage based on protein requirement (0.8-1.5 g/kg/day) and nutritional status.
None Documented
None Documented
Not applicable; components are endogenous substances. Clinical effect (nitrogen balance) persists 4-6 hours post-infusion.
Variable; amino acids: 10–40 minutes (rapid distribution and metabolism); clinical context: continuous infusion required to maintain steady state
Amino acids undergo metabolism; excess nitrogen is excreted renally as urea (80-90%), with minimal biliary/fecal elimination (<5%). Dextrose is metabolized.
Renal: >80% as amino acids and metabolites; fecal: negligible; biliary: <5%
Category C
Category C
Amino Acid Solution
Amino Acid Solution